Order Online! Now! Get your $50 coupon for online order.
Order Online! Now! Get your $50 coupon for online order.
Get your basement membrane extract free sample to test now!
Get your basement membrane extract free sample to test now!
Time Limited Offer: Welcome Gift for New Customers !
Shipping Price Reduction for EU Regions
Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
GP0-V182E6 | HIV-1 (CN54) | Biotinylated HIV-1 [HIV-1/Clade B/C (CN54)] GP120 Protein, His,Avitag™ | ![]() |
![]() ![]() |
![]() ![]() |
GP4-V15223 | HIV-1 (CM244) | HIV-1 [HIV-1/Clade E (CM244)] GP120 Protein, His Tag | ![]() |
![]() ![]() |
![]() ![]() |
GP5-V15224 | HIV-1 (16055) | HIV-1 [HIV-1/Clade C (16055)] GP120 Protein, His Tag | ![]() |
![]() ![]() |
![]() ![]() |
GP4-V15227 | HIV-1 (CN54) | HIV-1 [HIV-1/Clade B/C (CN54)] GP120 Protein, His Tag | ![]() |
![]() ![]() |
![]() ![]() |
Immobilized Human CD4, Fc Tag (Cat. No. CD4-H5259) at 5 μg/mL (100 μL/well) can bind HIV-1 [HIV-1/Clade E (CM244)] GP120, His Tag (Cat. No. GP4-V15223) with a linear range of 20-156 ng/mL (QC tested).
Immobilized Human CD4, Fc Tag (Cat. No. CD4-H5259) at 5 μg/mL (100 μL/well) can bind Biotinylated HIV-1 [HIV-1/Clade B/C (CN54)] GP120, His,Avitag (Cat. No. GP0-V182E6) with a linear range of 0.156-1.25 μg/mL (QC tested).
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
COM-701 | COM-701 | Phase 2 Clinical | Compugen Ltd | Head and Neck Neoplasms; Solid tumours; Ovarian Neoplasms; Neoplasms; Triple Negative Breast Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Endometrial Neoplasms | Details |
SHR-2002 | SHR-2002 | Phase 1 Clinical | Suzhou Suncadia Biopharmaceuticals Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd | Neoplasms | Details |
GSK-4381562 | SRF-813; GSK-4381562 | Phase 1 Clinical | Surface Oncology Inc | Neoplasms | Details |
JS-009 | JS-009; TAB009 | Phase 1 Clinical | Solid tumours; Neoplasms | Details | |
PM-1009 | PM1009 | Phase 1 Clinical | Biotheus Inc | Solid tumours; Neoplasms; Lung Neoplasms | Details |
SIM-0348 | SIM-0348 | Phase 1 Clinical | Simcere Pharmaceutical Group Ltd | Solid tumours; Neoplasms | Details |
COM-701 | COM-701 | Phase 2 Clinical | Compugen Ltd | Head and Neck Neoplasms; Solid tumours; Ovarian Neoplasms; Neoplasms; Triple Negative Breast Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Endometrial Neoplasms | Details |
SHR-2002 | SHR-2002 | Phase 1 Clinical | Suzhou Suncadia Biopharmaceuticals Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd | Neoplasms | Details |
GSK-4381562 | SRF-813; GSK-4381562 | Phase 1 Clinical | Surface Oncology Inc | Neoplasms | Details |
JS-009 | JS-009; TAB009 | Phase 1 Clinical | Solid tumours; Neoplasms | Details | |
PM-1009 | PM1009 | Phase 1 Clinical | Biotheus Inc | Solid tumours; Neoplasms; Lung Neoplasms | Details |
SIM-0348 | SIM-0348 | Phase 1 Clinical | Simcere Pharmaceutical Group Ltd | Solid tumours; Neoplasms | Details |
This web search service is supported by Google Inc.